Bright Minds Biosciences (DRUG) Total Non-Current Liabilities (2022 - 2025)
Bright Minds Biosciences' (DRUG) quarterly Total Non-Current Liabilities came in at $82604.9 in Q3 2024, up 120.1% YoY from $37530.8 in Q4 2023, and up 117.3% on a QoQ basis from -$477585.4 in Q2 2024.
Powered by 
Analysis
Bright Minds Biosciences (DRUG) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Bright Minds Biosciences (DRUG) has 3 years of Total Non-Current Liabilities data on file, last reported at $82604.9 in Q3 2024.
- Quarterly Total Non-Current Liabilities rose 120.1% year-over-year to $82604.9 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $82604.9 (up 120.1% YoY) and the FY2024 annual result came in at $82604.9, up 120.1% from the prior year.
- Total Non-Current Liabilities climbed to $82604.9 in Q3 2024, from -$477585.4 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $292813.2 in Q2 2022 to a low of -$477585.4 in Q2 2024.
- A 3-year average of -$65315.1 and a median of $10354.7 in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 120.1% in 2024, down 561.22% in 2024.
- Tracing DRUG's Total Non-Current Liabilities over 3 years: stood at -$183567.2 in 2022, then surged by 108.93% to $16399.2 in 2023, then jumped by 403.71% to $82604.9 in 2024.
- The last three Total Non-Current Liabilities figures came in at $82604.9 (Q3 2024), -$477585.4 (Q2 2024), and $10354.7 (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Bright Minds Biosciences | 459.66 Mn | 237.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 1.73 Mn |
| Sep 30, 2024 | 82,604.86 |
| Jun 30, 2024 | -477,585.39 |
| Mar 31, 2024 | 10,354.71 |
| Dec 31, 2023 | 16,399.24 |
| Sep 30, 2023 | -410,991.28 |
| Jun 30, 2023 | -72,228.27 |
| Mar 31, 2023 | 154,364.28 |
| Dec 31, 2022 | -183,567.22 |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 292,813.19 |